🇺🇸 FDA

Company profile · Sponsor

ADIAL

ADIAL PHARMACEUTICALS, INC.

ADIL · NYSE pharma CHARLOTTESVILLE, VA, USA
Pipeline
6
Drugs
1
Patents
1

Quick answer

ADIAL (ADIL) is a pharma company. headquartered in CHARLOTTESVILLE, VA, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 1 drug, and 1 patent to this profile..

Company facts

Ticker ADIL
Exchange NYSE
Company type pharma
Headquarters CHARLOTTESVILLE, VA, USA
SEC CIK 0001513525

Pipeline (6)

Search pipeline →

  1. AD04 (ondansetron)

    ADIAL

    Alcohol Use Disorder

    phase 3 small molecule completed

    1 trial

  2. Axitinib

    ADIAL

    Melanoma

    phase 2 small molecule completed

    1 trial

  3. Trametinib (GSK1120212)

    ADIAL

    Melanoma

    phase 2 small molecule completed

    1 trial

  4. Erythromycin lactobionate

    ADIAL

    Diabetes Mellitus, Type 1

    phase 1 small molecule completed

    1 trial

  5. Nizatidine

    ADIAL

    Gastroparesis

    phase 1 small molecule completed

    1 trial

  6. rhBMP-2 placement

    ADIAL

    Tooth Loss

    mab completed

    1 trial

Drugs (1)

Search drugs →

  1. hexachlorophene

    SOY-DOME

    TOPICAL approved

Patents (1)

Search patents →

  1. US 7183255

    Method for stabilizing blood pressure in hemodialysis subjects

    Expires Mon Feb 22 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is ADIAL?

ADIAL (ADIL) is a pharma company. headquartered in CHARLOTTESVILLE, VA, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 1 drug, and 1 patent to this profile..

What pipeline programs does ADIAL sponsor?

We track 6 ClinicalTrials.gov-linked programs for ADIAL, including AD04 (ondansetron) and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does ADIAL company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.